This article is available to members only. Please enjoy the abstract for free. Subscribe for instant access to the full article.

This content is restricted to subscribers

Continue Reading...

Did you know members enjoy unlimited free PDF downloads as part of their subscription? Subscribe today for instant access to this article and our entire library in your preferred format. Alternatively, you can purchase the PDF of this article individually.

Subscribe Now

Already a member? Login

  1. Japan Drug Information Institute in Pregnancy, National Center for Child Health and Development, Tokyo, Japan
  2. Social Pharmacy and Regulatory Science, Showa Pharmaceutical University, Tokyo, Japan
  3. Corresponding author: Naho Yakuwa, BPharm, Japan Drug Information Institute in Pregnancy, National Center for Child Health and Development, Okura 2-10-1, Setagaya-ku, Tokyo 157-8535, Japan ([email protected]).
  4. Department of Biostatistics M&D Data Science Center, Tokyo Medical and Dental University, Tokyo, Japan
  5. Department of Biostatistics M&D Data Science Center, Tokyo Medical and Dental University, Tokyo, Japan
  6. Japan Drug Information Institute in Pregnancy, National Center for Child Health and Development, Tokyo, Japan
  7. Department of Pediatrics, Teikyo University, Tokyo, Japan
  8. Japan Drug Information Institute in Pregnancy, National Center for Child Health and Development, Tokyo, Japan
  9. Japan Drug Information Institute in Pregnancy, National Center for Child Health and Development, Tokyo, Japan
  10. Japan Drug Information Institute in Pregnancy, National Center for Child Health and Development, Tokyo, Japan
  11. Department of Pharmaceuticals, National Center for Child Health and Development, Tokyo, Japan
  12. Japan Drug Information Institute in Pregnancy, National Center for Child Health and Development, Tokyo, Japan
  13. Center for Maternal-Fetal, Neonatal and Reproductive Medicine, Department of Perinatology, National Center for Child Health and Development, Tokyo, Japan
  14. Japan Drug Information Institute in Pregnancy, National Center for Child Health and Development, Tokyo, Japan
  15. Japan Drug Information Institute in Pregnancy, National Center for Child Health and Development, Tokyo, Japan
  16. Department of Pharmaceuticals, National Center for Child Health and Development, Tokyo, Japan
  17. Japan Drug Information Institute in Pregnancy, National Center for Child Health and Development, Tokyo, Japan
  18. Center for Maternal-Fetal, Neonatal and Reproductive Medicine, Department of Perinatology, National Center for Child Health and Development, Tokyo, Japan
  1. Kendig S, Keats JP, Hoffman MC, et al. Consensus bundle on maternal mental health: perinatal depression and anxiety. Obstet Gynecol. 2017;129(3):422–430. PubMed CrossRef
  2. Jones I, Chandra PS, Dazzan P, et al. Bipolar disorder, affective psychosis, and schizophrenia in pregnancy and the post-partum period. Lancet. 2014;384(9956):1789–1799. PubMed CrossRef
  3. Orsolini L, Valchera A, Vecchiotti R, et al. Suicide during perinatal period: epidemiology, risk factors, and clinical correlates. Front Psychiatry. 2016;7:138. PubMed CrossRef
  4. Takeda S, Takeda J, Murakami K, et al. Annual Report of the Perinatology Committee, Japan Society of Obstetrics and Gynecology, 2015: proposal of urgent measures to reduce maternal deaths. J Obstet Gynaecol Res. 2017;43(1):5–7. PubMed CrossRef
  5. Damkier P, Christensen LS, Broe A. Patterns and predictors for prescription of psychotropics and mood-stabilizing antiepileptics during pregnancy in Denmark 2000-2016. Br J Clin Pharmacol. 2018;84(11):2651–2662. PubMed CrossRef
  6. Reutfors J, Cesta CE, Cohen JM, et al. Antipsychotic drug use in pregnancy: a multinational study from ten countries. Schizophr Res. 2020;220:106–115. PubMed CrossRef
  7. Park Y, Huybrechts KF, Cohen JM, et al. Antipsychotic medication use among publicly insured pregnant women in the United States. Psychiatr Serv. 2017;68(11):1112–1119. PubMed CrossRef
  8. Cohen LS, Viguera AC, McInerney KA, et al. Reproductive safety of second-generation antipsychotics: current data from the Massachusetts General Hospital National Pregnancy Registry for atypical antipsychotics. Am J Psychiatry. 2016;173(3):263–270. PubMed CrossRef
  9. Viguera AC, Freeman MP, Góez-Mogollón L, et al. Reproductive safety of second-generation antipsychotics: updated data from the Massachusetts General Hospital National Pregnancy Registry for atypical antipsychotics. J Clin Psychiatry. 2021;82(4):20m13745. PubMed CrossRef
  10. Cohen LS, Góez-Mogollón L, Sosinsky AZ, et al. Risk of major malformations in infants following first-trimester exposure to quetiapine. Am J Psychiatry. 2018;175(12):1225–1231. PubMed CrossRef
  11. Freeman MP, Viguera AC, Góez-Mogollón L, et al. Reproductive safety of aripiprazole: data from the Massachusetts General Hospital National Pregnancy Registry for Atypical Antipsychotics. Arch Women Ment Health. 2021;24(4):659–667. PubMed CrossRef
  12. Huybrechts KF, Hernández-Díaz S, Patorno E, et al. Antipsychotic use in pregnancy and the risk for congenital malformations. JAMA Psychiatry. 2016;73(9):938–946. PubMed CrossRef
  13. Ellfolk M, Leinonen MK, Gissler M, et al. Second-generation antipsychotic use during pregnancy and risk of congenital malformations. Eur J Clin Pharmacol. 2021;77(11):1737–1745. PubMed CrossRef
  14. McKenna K, Koren G, Tetelbaum M, et al. Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study. J Clin Psychiatry. 2005;66(4):444–449, quiz 546. PubMed CrossRef
  15. Habermann F, Fritzsche J, Fuhlbrück F, et al. Atypical antipsychotic drugs and pregnancy outcome: a prospective, cohort study. J Clin Psychopharmacol. 2013;33(4):453–462. PubMed CrossRef
  16. Kulkarni J, Worsley R, Gilbert H, et al. A prospective cohort study of antipsychotic medications in pregnancy: the first 147 pregnancies and 100 one year old babies. PLoS One. 2014;9(5):e94788. PubMed CrossRef
  17. Raffi ER, Nonacs R, Cohen LS. Safety of psychotropic medications during pregnancy. Clin Perinatol. 2019;46(2):215–234. PubMed CrossRef
  18. Japan Drug Information Institute in Pregnancy website. https://www.ncchd.go.jp/kusuri/. Accessed July 2, 2019.
  19. Murashima A, Yakuwa N, Koinuma S, et al. The advances in dealing with the safety of medicated drugs in pregnancy. Glob Health Med. 2021;3(3):175–179. PubMed CrossRef
  20. Carandang RR, Sakamoto JL, Kunieda MK, et al. Roles of the Maternal and Child Health Handbook and other home-based records on newborn and child health: a systematic review. Int J Environ Res Public Health. 2021;18(14):7463. PubMed CrossRef
  21. Coding and classification. In: EUROCAT Guide 1.4: and Reference Documents: Instructions for the Registration and Surveillance of Congenital Anomalies. Ulster, United Kingdom: EUROCAT; 2016.
  22. Almaghlouth I, Pullenayegum E, Gladman DD, et al. Propensity score methods in rare disease: a demonstration using observational data in systemic lupus erythematosus. J Rheumatol. 2021;48(3):321–325. PubMed
  23. Allan V, Ramagopalan SV, Mardekian J, et al. Propensity score matching and inverse probability of treatment weighting to address confounding by indication in comparative effectiveness research of oral anticoagulants. J Comp Eff Res. 2020;9(9):603–614. PubMed CrossRef
  24. Jentink J, Loane MA, Dolk H, et al; EUROCAT Antiepileptic Study Working Group. Valproic acid monotherapy in pregnancy and major congenital malformations. N Engl J Med. 2010;362(23):2185–2193. PubMed CrossRef
  25. Tomson T, Battino D, Bonizzoni E, et al; EURAP study group. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol. 2011;10(7):609–617. PubMed CrossRef
  26. Yamane R, Hayashi M, Tanaka M, et al. Survey regarding pregnant women receiving novel antipsychotic agents. (in Japanese) Jpn J Drug Inform. 2008;11(1):35–38.
  27. International Clearinghouse for Birth Defects Surveillance and Research JAPAN. https://icbdsr-j.jp/2018data.html. Accessed June 18, 2021.
  28. Martínez-Frías ML, Rodríguez-Pinilla E. Problems of using data from Teratology Information Services (TIS) to identify putative teratogens. Teratology. 1999;60(2):54–55. PubMed CrossRef
  29. Ornoy A, Mastroiacovo P. More on data from teratogen information systems (TIS). Teratology. 2000;61(5):327–328. PubMed CrossRef
  30. Yakuwa N, Nakajima K, Koinuma S, et al. Perception of pregnant Japanese women regarding the teratogenic risk of medication exposure during pregnancy and the effect of counseling through the Japan drug information institute in pregnancy. Reprod Toxicol. 2018;79:66–71. PubMed CrossRef